nach oben

Current Geriatrics Reports

Erschienen in:

13.07.2018 | Pulmonology and Respiratory Care (D Breen, Section Editor)

Diffuse Parenchymal Lung Diseases in the Elderly

verfasst von: Sinead M. Walsh, Anthony W. O’Regan

Erschienen in: Current Geriatrics Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Diffuse parenchymal lung diseases comprise a heterogeneous group of disorders with varying clinical, physiologic, radiographic and pathologic presentations. Age of onset varies considerably. Interstitial lung abnormalities, and in particular, idiopathic pulmonary fibrosis (IPF), occur much more commonly in older persons. In recent years, advances have been made in understanding IPF pathogenesis and changes have occurred in relation to how IPF is managed.

Recent Findings

The cause of IPF remains unclear. It is thought that a non-specific injury in susceptible individuals triggers a progressive fibrotic response. Genetic susceptibility is increasingly recognised. Multidisciplinary team input is essential for making a diagnosis. Although, originally thought to be an inflammatory process, it has been shown that anti-inflammatory therapies may, in fact, be harmful to the patient. Two anti-fibrotic therapies (pirfenidone and nintedanib) are now available. There is a better recognition of prognosis and improved symptom control and management of end of life issues.

Summary

As life expectancy increases, further studies are necessary to assess the impact and natural history of interstitial lung diseases in the elderly.

Wells AU, Kokosi MA. Subclinical interstitial lung abnormalities: toward the early detection of idiopathic pulmonary fibrosis? Am Thoracic Soc. 2016;

Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA. 2016;315(7):672–81.CrossRefPubMedPubMedCentral

Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and progression of interstitial lung abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med. 2016;194(12):1514–22.CrossRefPubMedPubMedCentral

Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016:00477–2016.

•• Patterson KC, Shah RJ, Porteous MK, Christie JD, D’Errico CA, Chadwick M, et al. Interstitial lung disease in the elderly. Chest. 2017;151(4):838–44. Describes the diagnoses, clinical characteristics and outcomes of patients who were elderly at the time of ILD diagnosis. CrossRefPubMed

Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, et al. Workshop on idiopathic pulmonary fibrosis in older adults. Chest. 2010;138(3):693–703.CrossRefPubMedPubMedCentral

Snell N, Strachan D, Hubbard R, Gibson J, Limb E, Gupta R, et al. Burden of lung disease in the UK; findings from the British Lung Foundation’s ‘respiratory health of the nation’ project. Eur Respiratory Soc; 2016.

Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–5.CrossRefPubMedPubMedCentral

Schwartz D, Helmers R, Galvin J, Van Fossen D, Frees K, Dayton C, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1994;149(2):450–4.CrossRefPubMed

10.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King te Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011 2011/03/15;183(6):788–824.

11.

Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Ann Rev Pathol: Mech Dis. 2014;9:157–79.CrossRef

12.

Naik PK, Moore BB. Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med. 2010;4(6):759–71.CrossRefPubMedPubMedCentral

13.

Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84(1):52–9.CrossRefPubMedPubMedCentral

14.

Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–12.CrossRefPubMedPubMedCentral

15.

Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res/Fundam Mol Mech Mutagen. 2012;730(1):52–8.CrossRef

16.

Van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell A-M, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25(141):278–86.CrossRefPubMed

17.

• Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2017. Provides criteria to establish a confident and working diagnosis of IPF.

18.

Piciucchi S, Tomassetti S, Ravaglia C, Gurioli C, Gurioli C, Dubini A, et al. From “traction bronchiectasis” to honeycombing in idiopathic pulmonary fibrosis: a spectrum of bronchiolar remodeling also in radiology? BMC Pulm Med. 2016;16(1):87.CrossRefPubMedPubMedCentral

19.

•• Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82. IMPULSIS study is a seminal article showing improvement in outcomes with anti-fibrotic therapy (nintedanib). CrossRefPubMed

20.

Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One. 2014;9(2):e86716.CrossRefPubMedPubMedCentral

21.

Lentz RJ, Argento AC, Colby TV, Rickman OB, Maldonado F. Transbronchial cryobiopsy for diffuse parenchymal lung disease: a state-of-the-art review of procedural techniques, current evidence, and future challenges. J Thorac Dis. 2017;9(7):2186–203.CrossRefPubMedPubMedCentral

22.

Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265–75.CrossRefPubMed

23.

Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229–42.CrossRefPubMed

24.

•• Network IPFCR. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. The N Engl J Med 2012;366(21):1968. PANTHER study provided evidence against using prednisolone, azathioprine and NAC in IPF patients.

25.

Network IPFCR. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093–101.CrossRef

26.

•• King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92. ASCEND study is a seminal article showing improvement in outcomes with anti-fibrotic therapy (pirfenidone). CrossRefPubMed

27.

Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390–4.CrossRefPubMedPubMedCentral

28.

Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369–76.CrossRefPubMedPubMedCentral

29.

Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4(5):381–9.CrossRefPubMed

30.

Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014;14(1):139.CrossRefPubMedPubMedCentral

31.

Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis. 2017;9(8):2684–91.CrossRefPubMedPubMedCentral

32.

Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Libr 2014.

33.

• Bell EC, Cox NS, Goh N, Glaspole I, Westall GP, Watson A, et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev. 2017;26(143):160080. Oxygen therapy during exercise in ILD had no effects on dyspnoea, although an increase in exercise capacity was noted. CrossRefPubMed

34.

Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017;26(143):160027.CrossRefPubMed

35.

• Rush B, Wiskar K, Berger L, Griesdale D. The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: a nationwide retrospective cohort analysis. Respir Med. 2016;111:72–6. IPF patients who are mechanically ventilated do badly, with a mortality rate of 50%. CrossRefPubMed

36.

• Rajala K, Lehto JT, Saarinen M, Sutinen E, Saarto T, Myllärniemi M. End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliative Care. 2016;15(1):85. End of life decisions were made very late in patients with IPF. CrossRefPubMedPubMedCentral

Titel: Diffuse Parenchymal Lung Diseases in the Elderly
verfasst von: Sinead M. Walsh
Anthony W. O’Regan
Publikationsdatum: 13.07.2018
Verlag: Springer US
Erschienen in: Current Geriatrics Reports / Ausgabe 3/2018
Elektronische ISSN: 2196-7865
DOI: https://doi.org/10.1007/s13670-018-0249-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Diffuse Parenchymal Lung Diseases in the Elderly

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Muscle Wasting in the Hospitalised COPD Patients—How Can it Be Prevented and Treated?

Malignant Pleural Effusions—Personalised Management

Public Health Nutrition Programs for the Elderly: Epidemiological Basis

Mediterranean Diet to Promote Healthy Aging

Implementing Medical Nutritional Therapy Through Dietary Patterns in Prevention and Treatment of Diabetes

Tailoring Treatment in Obstructive Lung Disease: Asthma, COPD, Asthma/COPD Overlap and Eosinophilic COPD

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin